文献速递消化系统肿瘤

循环DNA分析快速检测可操作突变以选择转移性结直肠癌患者接受抗EGFR治疗的临床效用

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
PubMed 文献 · Ann Oncol · 2017-01-01

该前瞻性多中心盲法研究纳入140例转移性结直肠癌患者,比较ctDNA与肿瘤组织分析的一致性和数据周转时间。ctDNA检出KRAS、NRAS、BRAF突变率分别为59%、11.8%、14.4%,高于组织分析的44%、8.8%、7.2%;组织中位周转时间16天,ctDNA为2天。结论认为ctDNA可替代肿瘤组织分析并显著缩短周转时间。

要点

  • ctDNA检出KRAS、NRAS、BRAF突变率分别为59%、11.8%、14.4%,组织分析为44%、8.8%、7.2%。
  • 肿瘤组织中位数据周转时间16天,ctDNA分析为2天。
  • 不一致样本分析显示活检、采血与组织采集间隔长、采血时肿瘤已切除、肿瘤部位或组织类型可能影响一致性。

核心结论

  • ctDNA可替代肿瘤组织分析,并通过大幅缩短数据周转时间体现临床效用。

研究设计与样本

  • 实时盲法前瞻性多中心临床研究,纳入140例转移性结直肠癌患者,比较ctDNA与肿瘤组织分析的一致性和数据周转时间,结果按STARD标准呈现并结合患者临床结局讨论。

主要发现

  • ctDNA分析检出KRAS突变患者59%、NRAS突变11.8%、BRAF突变14.4%,组织分析分别为44%、8.8%、7.2%。
  • 肿瘤组织中位数据周转时间16天,ctDNA分析为2天。
  • 不一致样本分析显示,使用活检、肿瘤组织与血液采集间隔长、采血时肿瘤已切除、肿瘤部位或所分析组织类型似乎影响一致性。
  • 不一致患者中抗EGFR反应(RAS状态)和预后(BRAF状态)的临床数据与血浆分析确定的突变状态似乎不矛盾。
  • ctDNA分析(n=119)首次呈现RAS和BRAF热点突变分布,45%的患者存在多个突变(最多5个),仅24%的患者两个基因均为野生型。

关键数值与推荐

  • ctDNA检出KRAS突变59%、NRAS突变11.8%、BRAF突变14.4%,组织分析分别为44%、8.8%、7.2%。
  • 肿瘤组织中位数据周转时间16天,ctDNA分析为2天。
  • ctDNA分析(n=119)中45%的患者存在多个突变(最多5个),仅24%的患者两个基因均为野生型。

临床怎么用

  • 在标准管理照护下,ctDNA分析可用于快速检测可操作突变以选择转移性结直肠癌患者接受抗EGFR治疗,并大幅缩短数据周转时间。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While tumor-tissue remains the 'gold standard' for genetic analysis in cancer patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis from blood samples. Here, we broaden our previous study on the clinical validation of plasma DNA in metastatic colorectal cancer patients, by evaluating its clinical utility under standard management care. PATIENTS AND METHODS: Concordance and data turnaround-time of ctDNA when compared with tumor-tissue analysis were studied in a real-time blinded prospective multicenter clinical study (n = 140 metastatic colorectal patients). Results are presented according to STARD criteria and were discussed in regard with clinical outcomes of patients. RESULTS: Much more mutations were found by ctDNA analysis: 59%, 11.8% and 14.4% of the patients were found KRAS, NRAS and BRAF mutant by ctDNA analysis instead of 44%, 8.8% and 7.2% by tumor-tissue analysis. Median tumor-tissue data turnaround-time was 16 days while 2 days for ctDNA analysis. Discordant samples analysis revealed that use of biopsy, long delay between tumor-tissue and blood collection and resection of the tumor at time of blood draw, tumor site, or type of tissue analyzed seem to affect concordance. Altogether, the clinical data with respect to the anti-epidermal growth factor receptor response (RAS status) and the prognosis (BRAF status) of those discordant patients do not appear contradictory to the mutational status as determined by plasma analysis. Lastly, we present the first distribution profile of the RAS and BRAF hotspot mutations as determined by ctDNA analysis (n = 119), revealing a high proportion of patients with multiple mutations (45% of the population and up to 5 mutations) and only 24% of WT scored patients for both genes. Mutation profile as determined from ctDNA analysis with using various detection thresholds highlights the importance of the test sensitivity. CONCLUSION: Our study showed that ctDNA could replace tumor-tissue analysis, and also clinical utility of ctDNA analysis by considerably reducing data turnaround time.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Thierry AR, El Messaoudi S, Mollevi C, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017. PMID: 28911069. doi:10.1093/annonc/mdx330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。